UK markets open in 5 hours 44 minutes

Immunicum AB (publ) (IMMU.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
5.37+0.12 (+2.29%)
At close: 12:59PM CEST
Full screen
Previous close5.25
Open5.25
Bid5.37 x 0
Ask5.38 x 0
Day's range5.18 - 5.79
52-week range4.90 - 12.24
Volume189,967
Avg. volume352,258
Market cap892.317M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.20
Earnings date18 Feb 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est21.70
  • Globe Newswire

    Immunicum Announces Presentations at the European Hematology Association (EHA) 2021 Virtual Congress

    Press Release 12 May 2021 Immunicum Announces Presentations at the European Hematology Association (EHA) 2021 Virtual Congress Immunicum AB (publ; IMMU.ST) today announced that it will be presenting two posters on its off-the-shelf relapse vaccine DCP-001 at the EHA 2021 Virtual Congress, to be held from June 9-17, 2021. The accepted abstracts are now published on the conference website and accessible through www.ehaweb.org. The presentations include interim immunological results from the Phase II ADVANCE II study, demonstrating DCP-001’s ability to induce immune responses to a broad range of tumor-associated antigens in acute myeloid leukemia (AML) patients, as well as preclinical results of enhanced efficacy when combining DCP-001 with established AML treatment regimens. “From the interim clinical data published in the abstract today, we are excited to see that DCP-001 induces a range of detectable immune responses in AML patients participating in our ongoing ADVANCE II study,” said Jeroen Rovers, Chief Medical Officer at Immunicum. “These results demonstrate that DCP-001 has the ability to activate the immune system and induce a broad cellular anti-tumor response, with the aim to ultimately prevent leukemia relapse in these patients. We continue to enroll patients in ADVANCE II and remain on track to present more efficacy results before the end of this year.” The clinical abstract on DCP-001 (EP458) in the ongoing ADVANCE II clinical study covers data on patients who completed the full vaccination schedule and demonstrates that patients treated with DCP-001 present with inflammation and infiltration of CD4+ and CD8+ T cells at the site of injection. In the blood of patients, an increase in CD8+ T cells and specific immune responses to known tumor-associated antigens present in DCP-001, such as PRAME and WT-1, were observed. At the data cutoff, DCP-001 was able to successfully convert the measurable residual disease (MRD) status from positive to negative in 2 out of 5 patients with immune response data available. In these patients, multiple antigenic responses and high levels of infiltrating immune cells at the injection site were observed. The second abstract (EP403) covers preclinical data on the combination of DCP-001 with the established AML treatment agents venetoclax (VEN) and 5-azacitidine (5-AZA). Humanized immunocompetent mice were assigned to the triple combination of DCP-001 with VEN and 5-AZA, DCP-001 alone, VEN and 5-AZA or the control group. Results demonstrated that all treatment groups reduced tumor growth as compared to the control group and that average tumor volume was significantly reduced in the triple combination group as compared to all other groups, supporting the use of DCP-001 as add-on treatment with established AML treatment regimens in AML patients. Abstracts for the EHA 2021 Virtual Congress were published today and are available through this link. E-posters will be available for registered attendees through the Virtual Congress platform starting Friday, June 11, 09:00 CEST. Details on the presentations are as follows: Title:Induced systemic T-cell specific responses the multiple tumor-associated antigens after allogenic leukemia-derived dendritic cell vaccine DCP-001 in AML patients with persistent MRDAbstract #:EP458Session Topic:Acute Myeloid Leukemia – Clinical Title:Enhanced efficacy of the DCP-001 relapse vaccine when combined with Venetoclax and 5-Azaciticidine in a humanised immunocompetent mouse model of AMLAbstract #:EP403Session Topic:Acute myeloid leukemia - Biology & Translational Research For more information, please contact: Erik MantingChief Executive OfficerTelephone: +31 713 322 627E-mail: ir@immunicum.com Investor Relations Sijme ZeilemakerHead of Investor Relations & Corporate CommunicationTelephone: +46 8 732 8400E-mail: ir@immunicum.com Media Relations Eva Mulder and Sophia HergenhanTrophic CommunicationsTelephone: +49 175 222 57 56E-mail: immu@trophic.eu About Immunicum AB (publ) Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com Attachment 20210512_Immunicum_EHA_Abstracts_ENG_final

  • Globe Newswire

    Report from the Annual General Meeting of Immunicum AB (publ) on 4 May 2021

    Press Release 4 May 2021 Report from the Annual General Meeting of Immunicum AB (publ) on 4 May 2021 At the annual general meeting (the “AGM”) of Immunicum AB (publ), reg. no 556629-1786, (the “Company”), on 4 May 2021 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the AGM and the complete proposals, which have previously been published and are available on the Company’s website, www.immunicum.com. Adoption of the balance sheet and income statement, disposition regarding the Company’s results and discharge from liabilityThe AGM adopted the Company’s balance sheet and income statement and consolidated income statement and consolidated balance sheet. The AGM resolved that the Company’s accumulated losses shall be appropriated so that SEK 106,307,963 is settled against the share premium reserve and that the remaining SEK 717,815,244 is carried forward and that no dividends shall be paid for the financial year 2020. The AGM also discharged the board members and the managing director from liability for the financial year 2020. The AGM resolve to approve the board of directors’ remuneration report for 2020. Remuneration to the board of directors and auditor The AGM decided that remuneration to the board of directors shall amount to SEK 2,300,000, to be distributed as follows: The chairman of the board of directors is entitled to remuneration of SEK 600,000 and other board members are entitled to remuneration of SEK 275,000 per member. Furthermore, it is proposed that a fee for committee work be paid in the amount of SEK 70,000 to the chairman of the audit committee, SEK 40,000 to each of the other board members in the audit committee, SEK 50,000 to the chairman of the scientific committee, SEK 25,000 to each of the other board members in the Scientific Committee, SEK 35,000 to the Chairman of the Remuneration Committee and SEK 20,000 to each of the other Board members of the Remuneration Committee. In accordance with the nomination committee’s proposal each board member is recommended, for the period until the next annual general meeting, to acquire shares in the Company corresponding to an amount of at least 100 % of the board of directors’ fee after deduction of taxes in the event the board member has not already invested in shares in the Company for an amount equivalent to the fee. The AGM decided that remuneration to the auditor shall be paid according to approved invoice. Election of board members and auditorThe AGM resolved that the board of directors shall consist of six ordinary board members without deputies. For the period until the end of the next annual general meeting the AGM re-elected the present board members Sven Andreasson, Dharminder Chahal, Andrea van Elsas, Christine Lind and Helén Tuvesson. Hans Preusting was elected as new board member. Charlotte Edenius and Steven Glazer have requested to not be re-elected. Christine Lind was re-elected as chairman of the board of directors. The AGM resolved to re-elect the registered audit firm Ernst & Young AB as auditor for the period until the end of the next annual general meeting. Ernst & Young AB has informed that Anna Svanberg will remain as auditor in charge. Resolution regarding principles for the appointment and assignment of the nomination committeeThe AGM resolved to adopt principles for the appointment and assignment of the nomination committee in accordance with the nomination committee’s proposal. Resolution regarding amendment of the articles of associationThe AGM resolved to amend the articles of association in accordance with the board of directors’ proposal, whereby the material change is that the board of director’s registered office is changed from Gothenburg to Stockholm. Resolution regarding amendment of guidelines for remuneration to senior executivesThe AGM resolved to amend the guidelines for remuneration to senior executives in accordance with the board of directors’ proposal, entailing that the limitation for variable remuneration is increased from 35 percent to 50 percent of the fixed annual salary and the limitation for pension is increased from 25 percent to 30 percent for all senior executives. Resolution regarding performance based LTI 2021/2024The AGM resolved to implement a performance based incentive program based on a maximum of 1,678,453 employee stock options for management and key employees in Immunicum and a restricted share unit program based on a maximum of 834,300 restricted share units for other employees in accordance with the board of directors’ proposal. Each employee stock option and restricted share unit entitles the holder the right to subscribe for one (1) new share in the Company during the period commencing on 1 September 2024 up to and including 31 October 2024. The subscription price when exercising the employee stock option shall be equivalent to 140 per cent of the volume-weighted average price paid during the period commencing at 5 May 2021 up until and including 19 May 2021 of the noted paid prices (according to Nasdaq Stockholm’s official rating list) for shares in the Company. The subscription price when exercising the restricted share unit shall correspond to the quota value of the shares in the Company. The employee stock options and restricted share units are allotted free of charge to the participants. Authorization for the board of directors to decide on new share issues and issues of warrants and/or convertiblesThe AGM resolved to authorize the board of directors to resolve, for the period until the end of the next annual general meeting, at one or more occasions and with or without deviation from the shareholders’ preferential rights, to issue new shares, warrants and/or convertibles for cash payment and/or with provision of non-cash consideration or set-off or otherwise. The number of shares, or warrants or convertibles that entitle subscription of a number of shares, that may be issued in directed issues shall not exceed 20 percent of the Company’s registered number of shares on a fully diluted basis, i.e. including outstanding warrants in the Company, at the time of the board of director’s first resolution pursuant to the authorization. In addition to the limitation of 20 percent for directed issues, the board shall be entitled to issue shares, or warrants or convertibles that entitle subscription of a number of shares, without deviation from the shareholders’ preferential rights up to a maximum of 10 percent of the Company’s registered number of shares on a fully diluted basis. The information in this press release is information that Immunicum AB (publ) is obliged to disclose pursuant to Nasdaq Stockholm’s Rule Book for Issuers. The information was released for public disclosure through the agency of the contact persons set out below 12:00 CET on 4 May, 2021. FOR MORE INFORMATION, PLEASE CONTACT: Christine LindInterim Chairman of the Board of DirectorsTelephone: +46 8 732 8400E-mail: ir@immunicum.com INVESTOR RELATIONS Sijme ZeilemakerHead of Investor Relations & Corporate CommunicationTelephone: +46 8 732 8400E-mail: ir@immunicum.com MEDIA RELATIONS Eva Mulder and Sophia HergenhanTrophic CommunicationsTelephone: +49 175 222 57 56E-mail: immu@trophic.eu ABOUT IMMUNICUM AB (PUBL) Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com Attachment 20210504_Immunicum_AGM Report 2021_ENG_PDF

  • Globe Newswire

    Immunicum AB (publ) Interim Report January – March 2021

    Press Release 4 May 2021 Immunicum AB (publ) Interim Report January – March 2021 JANUARY – MARCH IN SUMMARY Net sales for the period amounted to KSEK - (-)*.Result for the quarter amounted to KSEK -41,571 (-12,018).Earnings and diluted earnings per share totaled SEK -0.16 (-0.25)*.Christine Lind was appointed interim chairman and Dharminder Chahal and Andrea van Elsas were elected as new members of Immunicum’s Board of Directors.Immunicum received Orphan Drug Designation for ilixadencel as a treatment of soft tissue sarcoma, including gastrointestinal stromal tumors (GIST), from the FDA and as a treatment of GIST from the EMA.Immunicum signed a long-term lease to move its in-house research and process development activities into a new facility in Leiden, the Netherlands by 2022.Immunicum established an updated Executive Management Team with Erik Manting as Chief Executive Officer, Alex Karlsson-Parra as Chief Scientific Officer, Jeroen Rovers as Chief Medical Officer and Lotta Ferm as interim Chief Financial Officer.Immunicum announced encouraging signs of survival benefit in the Phase II MERECA trial of ilixadencel in kidney cancer, with the co-primary endpoint of median overall survival reached at 35.6 months for the ilixadencel treatment group versus the 25.3 months for the sunitinib control group. COVID-19 To date, Immunicum has not experienced any major impact to its operations owing to the Covid-19 pandemic. For further information, go to the risk section on page 17. SIGNIFICANT EVENTS AFTER END OF PERIOD Immunicum initiated a research collaboration with Professor Bhardwaj from Icahn School of Medicine at Mount Sinai in New York City. FINANCIAL SUMMARY* Q1Full YearKSEK unless otherwise stated202120202020Operating profit/loss-40,780-11,232-86,027Net profit/loss-41,571-12,018-89,248Earnings per share, before and after dilution (SEK)-0.25-0.16-1.17Cash118,96036,34836,348Shareholders equity619,10019,50619,506Number of employees301929 * On December 21, 2020, Immunicum AB acquired DCprime BV. The transaction resulted in the owners of the acquired company (DCprime) havingdeemed control of the acquiring company (Immunicum). The acquisition is therefore accounted for as a reverse acquisition. The consolidated financial statements, for prior period, thus only consist of DCprime BV until the time of acquisition, December 21, 2020. This means that the result for full year 2020 refers to DCprime BV’s result for the entire financial year and Immunicum AB’s result for the last 10days of 2020. The result for 2021 refers to the consolidated group. CEO COMMENT - FIRST QUARTER In the first quarter of 2021, Immunicum solidified its management team and organizational focus following the merger with DCprime. As a unified company we have a strong foundation and two programs delivering clinical results during 2021. Today Immunicum is a company with complementary therapeutic approaches addressing both solid and blood-borne tumors. This solid foundation based on decades of research in allogeneic dendritic cell biology has produced distinct product candidates addressing major challenges in today’s cancer therapy. The development of our lead programs will benefit from ongoing clinical evaluation. In a recent study update last February, the intratumoral immune primer ilixadencel has reported stronger response rates and extended survival in renal cell carcinoma. The ongoing Phase Ib/ II ILIAD trial is a key part of our strategy to demonstrate and position ilixadencel within the competitive landscape of modern cancer combination therapies, in which checkpoint inhibitors are an important pillar. The focus of the Phase Ib will be on establishing safety in the different indications that pembrolizumab (Keytruda®) is currently standard of care. We will use the trial results to drive the decision-making process and define ilixadencel’s potential in different combinations and indications, so this will be a clear value-inflection point that will determine the clinical development priorities for ilixadencel. Our cancer relapse vaccine DCP-001 is similarly entering a development phase important to its positioning within the competitive landscape of blood-borne tumors, specifically acute myeloid leukemia (AML). Interim results from the ongoing Phase II ADVANCE II trial provided a preview of its potential as monotherapy, and the top-line results for all patients towards Q4 2021 will be an important confirmation. Given the developments in the therapeutic landscape, this will again be an important value-inflection point that will drive the clinical priorities for DCP-001 in blood-borne tumors. In addition, an exciting opportunity is the potential expansion of DCP-001’s application into the treatment of solid tumors through the Phase I/II ALISON trial that will start enrolling patients during 2021. The ILIAD and ADVANCE II data will support the further clinical development of our programs and their positioning at the forefront of the cancer immunotherapy landscape. The potential of our products as combination therapies and as maintenance therapies further benefits from their excellent safety profile. Our scientific leadership will drive the expansion of our pipeline while supporting and validating the programs that are in clinical development. The research collaboration with Professor Bhardwaj at the Icahn School of Medicine at Mount Sinai in New York City is aimed at elucidating the specific pathways involved in the mechanisms of our pioneering programs with a research group that is at the frontier of this field. Scientific presentations at the Cancer Immunotherapy Annual Meeting and the plans to expand our in-house R&D facilities exemplify our commitment to invest into the research and process development of our products. There are a vast number of opportunities in our pipeline, with two programs in Phase II development and a deep portfolio of next-generation approaches that we are investigating. We have therefore used the first quarter of this year to recalibrate the company’s development priorities and will continue to do so based on the progress in our clinical studies. I feel privileged to become CEO of Immunicum following the merger with DCprime and to lead the organization in this important transition phase. We appreciate your support and are committed to deliver the results and progress that will ultimately drive value generation and the advanced development of novel therapies that could truly make a difference to cancer patients. ERIK MANTING Chief Executive Officer The full quarterly report is available on: http://immunicum.se/investors/financial-reports/ The information was submitted for publication, through the agency of the contact persons set out below, on May 4, 2021, at 8:00 am CET. FOR MORE INFORMATION, PLEASE CONTACT: Erik MantingChief Executive OfficerTelephone: +31 713 322 627E-mail: ir@immunicum.com INVESTOR RELATIONS Sijme ZeilemakerHead of Investor Relations & Corporate CommunicationTelephone: +46 8 732 8400E-mail: ir@immunicum.com MEDIA RELATIONS Eva Mulder and Sophia HergenhanTrophic CommunicationsTelephone: +49 175 222 57 56E-mail: immu@trophic.eu ABOUT IMMUNICUM AB (PUBL) Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com Attachments 20210504_Immunicum_1Q2021 Report_ENG_PDF Immunicum.Q1_ENG_Final.05.03.3